Disease Overview：Ovarian Cancer（OC）
Ovarian cancer is a malignant neoplasm originating in the ovarian epithelium, stroma, or germ cells, with epithelial ovarian carcinoma accounting for approximately 90% of cases. It is often asymptomatic in early stages, leading to late diagnosis—typically at advanced FIGO stages III or IV—when disease has spread beyond the pelvis. Risk factors include BRCA1/2 mutations, nulliparity, advanced age, and family history. Standard management involves comprehensive surgical staging and cytoreduction—ideally achieving no residual disease—followed by platinum-based chemotherapy (e.g., carboplatin/paclitaxel). For BRCA-mutated or homologous recombination–deficient tumors, PARP inhibitors (olaparib, niraparib) have significantly improved progression-free survival. Despite advances, five-year survival remains below 50% for advanced disease, underscoring the importance of multidisciplinary care, molecular profiling, and access to clinical trials.
China offers compelling advantages for international patients seeking ovarian cancer treatment. Leading oncology centers—such as Fudan University Shanghai Cancer Center and Peking Union Medical College Hospital—employ internationally trained gynecologic oncologists with extensive experience in ultra-radical surgery, HIPEC (hyperthermic intraperitoneal chemotherapy), and biomarker-guided targeted therapy. State-of-the-art infrastructure includes PET-MRI fusion imaging, next-generation sequencing platforms, and robotic-assisted laparoscopic systems. Clinical outcomes align with global benchmarks: published 5-year survival rates for stage III disease exceed 60% in high-volume centers, supported by robust postoperative surveillance protocols. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based standards of care.
As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients—handling hospital referrals, visa coordination, interpreter services, accommodation logistics, and transparent, itemized cost estimates upfront. Our clinical coordinators work closely with treating teams to ensure continuity of care, second opinions, and personalized follow-up planning.
Ovarian Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Ovarian Cancer (Gynecologic Oncology)
Non-Surgical / Medical Therapy
*Indications*: Advanced-stage (III–IV), recurrent disease, neoadjuvant therapy, or medically inoperable patients.
- •First-Line Chemotherapy (Carboplatin + Paclitaxel)
- *Cost per Cycle (3-week regimen)*: - Carboplatin (AUC 5–6): $280–$340 - Paclitaxel (175 mg/m²): $220–$290 - Antiemetics (ondansetron + dexamethasone IV): $45–$65 - Blood count & liver/kidney panel (pre-cycle): $35–$50 - Infusion nursing & monitoring (day-care): $110–$150 - *Total per cycle*: $690–$895 (6 cycles typical)
- •PARP Inhibitors (Maintenance)
- Olaparib (300 mg BID oral): $1,450–$1,720/month - Germline/somatic BRCA testing (NGS panel): $380–$520 - HRD assay (Myriad MyChoice CDx): $620–$790
Surgical / Procedural Options
*Indications*: Stages I–IV; optimal cytoreduction goal ≤1 cm residual disease.
- •Primary Debulking Surgery (PDS)
- *Preoperative Workup*: - Pelvic MRI + contrast: $210–$270 - CA-125 + HE4 + ROMA score: $45–$65 - Cardiopulmonary evaluation (ECG, echo, PFTs if indicated): $180–$240 - *Procedure Cost (open approach, full staging)*: - Total hysterectomy + bilateral salpingo-oophorectomy + omentectomy + pelvic/para-aortic lymphadenectomy + peritoneal biopsies: $4,200–$5,800 - Intraoperative frozen section pathology: $190–$260
- •Interval Debulking Surgery (IDS)
- *Cost range*: $3,900–$5,400 (lower due to reduced complexity vs. PDS)
Special/Complex Scenarios
- •Recurrent Platinum-Resistant Disease:
- •BRCA Wild-Type, HRD-Negative Recurrence:
- •Malignant Bowel Obstruction Palliation:
Quick Selection Guide
- •<60 years, Stage III–IV, good performance status: *PDS + adjuvant chemo + PARPi maintenance* — optimal survival benefit ($12,500–$16,200 total)
- •≥75 years or significant comorbidities (COPD, CHF): *Neoadjuvant chemo → IDS* — lower perioperative risk ($9,800–$13,400)
- •Stage I, low-grade serous or mucinous: *Fertility-sparing surgery (unilateral salpingo-oophorectomy)* — $3,400–$4,600, preserves ovarian function
- •Budget-constrained (<$5,000): *Single-agent carboplatin monotherapy (AUC 5) × 6 cycles* — $4,100–$5,100, modest efficacy but accessible
- •Platinum-resistant recurrence with ascites: *Paracentesis + intraperitoneal cisplatin (off-label)* — $1,200–$1,700/session, palliative symptom control
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Ovarian Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining Ovarian Cancer treatment with China top medical destinations:
